Please use this identifier to cite or link to this item:
Files in This Item:
There are no files associated with this item.
Title: Whey-Derived Peptides at the Heart of the COVID-19 Pandemic
Authors: Chamata, Yara; Jackson, Kim G.; Watson, Kimberly A.; Jauregi, Paula
Abstract: The renin-angiotensin system (RAS) is a key regulator of blood pressure and hypertension. Angiotensin-converting enzyme 2 (ACE2) and angiotensin-converting enzyme I (ACE) are two main components of the RAS that play a major role in blood pressure homeostasis. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses ACE2 as a receptor to enter cells. Despite some controversies, numerous studies have reported a significant association between the use of ACE inhibitors and reduced risk of COVID-19. In our previous studies, we produced and identified peptide sequences present in whey hydrolysates exhibiting high ACE inhibitory activity. Therefore, the aim of this work is to obtain an improved understanding of the function of these natural peptides as RAS inhibitors and investigate their potential therapeutic role in the COVID-19 pandemic. The molecular interactions between peptides IPP, LIVTQ, IIAE, LVYPFP, and human ACE2 were assessed by employing a molecular docking approach. The results show that natural whey-derived peptides have a dual inhibitory action against both ACE and ACE2. This dual activity distinguishes these ACE inhibitory peptides from synthetic drugs, such as Captopril and Lisinopril which were not shown to inhibit ACE2 activity, and may represent a potential strategy in the treatment of COVID-19.
Issue Date: 2021
Publisher: MDPI
Type: Article
DOI: 10.3390/ijms222111662
E-ISSN: 1422-0067
Funder: Department of Food and Nutritional Sciences at the University of Reading
Appears in Publication types:Artículos científicos

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.